CD8A and melanoma: Anti-CD20-mediated B cell depletion in melanoma patients led to decreased tumor-associated inflammation and CD8 T cell counts, with plasmablast-like cells demonstrating increased PD-1 T cell activation following in vitro anti-PD-1 blockade [111].